Should a Reduction in All-Cause Mortality Be the Goal When Assessing Preventive Medical Therapies?
dc.contributor.author | Sasieni, PD | en_US |
dc.contributor.author | Wald, NJ | en_US |
dc.date.accessioned | 2017-08-04T15:07:25Z | |
dc.date.issued | 2017-05-23 | en_US |
dc.date.submitted | 2017-07-19T14:12:23.555Z | |
dc.identifier.issn | 0009-7322 | en_US |
dc.identifier.uri | http://qmro.qmul.ac.uk/xmlui/handle/123456789/25062 | |
dc.format.extent | 1985 - 1987 | en_US |
dc.language.iso | en | en_US |
dc.relation.ispartof | CIRCULATION | en_US |
dc.subject | all-cause death | en_US |
dc.subject | cardiovascular disease | en_US |
dc.subject | cardiovascular events | en_US |
dc.subject | clinical trial | en_US |
dc.subject | statistical analysis | en_US |
dc.title | Should a Reduction in All-Cause Mortality Be the Goal When Assessing Preventive Medical Therapies? | en_US |
dc.type | Article | |
dc.rights.holder | © 2017 American Heart Association, Inc. | |
dc.identifier.doi | 10.1161/CIRCULATIONAHA.116.023359 | en_US |
pubs.author-url | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000401697500002&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=612ae0d773dcbdba3046f6df545e9f6a | en_US |
pubs.issue | 21 | en_US |
pubs.notes | 6 months | en_US |
pubs.publication-status | Published | en_US |
pubs.volume | 135 | en_US |